Photo: Aletta autonomous blood draw. Vitestro / IEEE Spectrum
You sit down
The machine finds the vein. Two heart trials stop.
You sit down and put your arm in the cradle. Aletta, from Vitestro, is the first autonomous blood draw the FDA has cleared for adults outside a hospital. Infrared light hunts for a vein. A puff of alcohol hits the skin. Ultrasound maps how deep the vessel runs. The needle comes down. In a Dutch trial of more than 1,600 people it succeeded on the first try in 94.5 percent of cases. No human has to touch you.
On Monday, September 7, 2026, we hold that arm to one pressure: who still holds the body when the machine is faster than the person, and when the trial leaves.
Novo Nordisk stopped HERMES and ATHENA, two trials of ziltivekimab meant to tame inflammation in heart failure. A monitoring committee saw little chance they would beat ZEUS, which already missed deaths, heart attacks, and strokes. ARTEMIS, after a heart attack, continues. Princeton's PACMAN loop on a tokamak runs in about 20 milliseconds. It predicted a tearing mode 200 milliseconds early. The physicists still set the goal.
A STAT reader wrote that a click, a signature, or a brief review should not magically transfer responsibility from an AI developer to a physician. China withdrew its pavilion from the Gwangju Biennale over Taiwan. The exhibition is titled You Must Change Your Life. The pavilion left. An Amazon Air Boeing 767, operated by 21 Air from San Juan, overran a Miami runway on Sunday. Fire. Injuries. Berlin Art Week is back. Summer is over.
A study of more than 270,000 people linked higher blood tyrosine to a shorter life in men, nearly a year. It did not test the supplement bottle. The arm is still in the cradle. Convergence is not the robot. It is whether a person is still in the room when the committee stops the trial, and when the click is asked to carry the blame.